Assessing the risk of COVID-19 reinfection and severe outcomes among individuals with substance use disorders: a retrospective study using real-world electronic health records
Open Access
Abstract
Objective Despite advancement in vaccines and treatments for COVID-19 over the past 2 years, many concerns remain about reinfection and waning immunity against COVID-19 and its variants, especially among people with substance use disorder (SUD). The study assessed the risk of COVID-19 reinfection and severe illness among adults with SUD and their vaccination status to inform management in this vulnerable population as the pandemic continues. Design Retrospective cohort study. Setting Nationwide electronic health records (TriNetX database) in the USA among adults with COVID-19 infection from January 2020 to June 2022. Participants Adults (age ≥18 years) who were infected by COVID-19, excluding those who had cancer or lived in nursing homes or palliative care facilities. Outcome measures COVID-19 reinfection was defined as a new diagnosis after 45 days of the initial infection. Logistic regression was applied to assess the OR of COVID-19 reinfection and severe outcomes within 30 day of reinfection for adults with alcohol (AUD), opioid (OUD), cocaine (CUD), stimulant (STUD), cannabis (CAUD) and other use disorders, controlled for demographic and comorbid conditions. Results The SUD cohort was 13%–29% more likely to be reinfected by COVID-19 and had significantly higher 30-day mortality. Adults with AUD, STUD and OUD were at greater risks (adjusted ORs, AORs=1.69–1.86) of emergency department, hospital and intensive care admissions after 30 days of reinfection. Individuals with SUD and multiple vaccines doses were associated with decreased risks of worse COVID-19 outcomes. Lower COVID-19 reinfection rates (AORs=0.67–0.84) were only found among individuals with AUD, CUD or CAUD who had COVID-19 vaccination. Conclusions Individuals with SUD had greater risks of COVID-19 reinfection and poor outcomes, especially those with OUD, STUD and AUD. Multiple vaccinations are recommended to reduce severe illness after COVID-19 reinfection in the SUD population.Keywords
This publication has 32 references indexed in Scilit:
- Addictions in the COVID-19 era: Current evidence, future perspectives a comprehensive reviewProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2021
- Substance Use Disorders and COVID-19: Multi-Faceted Problems Which Require Multi-Pronged SolutionsFrontiers in Psychiatry, 2020
- Collision of the COVID-19 and Addiction EpidemicsAnnals of Internal Medicine, 2020
- Mitigating and learning from the impact of COVID‐19 infection on addictive disordersAddiction, 2020
- Socioeconomic Disparities and Self-reported Substance Abuse-related Problems2018
- Perceived access and barriers to care among illicit drug users and hazardous drinkers: findings from the Seek, Test, Treat, and Retain data harmonization initiative (STTR)BMC Public Health, 2018
- Management of comorbid bipolar disorder and substance use disordersThe American Journal of Drug and Alcohol Abuse, 2017
- The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) StatementPLOS Medicine, 2015
- The comorbidity of depression and substance use disordersClinical Psychology Review, 2000
- The epidemiology of co-occurring addictive and mental disorders: Implications for prevention and service utilization.American Journal of Orthopsychiatry, 1996